Nano Pharmaceuticals
Market Cap
₹7 ₹7.00 Cr.
P/E
0.00
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
-1.00
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
55.44 %
Institutions
Institutions
-
Market cap
Market cap
7.00 Cr
No. of Shareholders
No. of Shareholders
18,444
OPM (%)
OPM (%)
-
PE
PE
-
Prom Holding
Prom Holding
25.85 %
ROCE (%)
ROCE (%)
-74.67
ROE (%)
ROE (%)
8.12
Sales
Sales
-
  • Adline Chem Lab
  • Hemo Organic
  • Ganga Pharma

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Price Range

See where the stock is trading versus its 52-week high and low.

Low
8
52W Range
High
17
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

6 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Adline Chem Lab Ltd. Business

Founded in 1990 in Ahmedabad, Kamron Laboratories Ltd produces tablets, capsules, and liquid orals. They aim to establish strong brands and be among top three in their segments and countries of operation.

Adline Chem Lab major competitors are Hemo Organic, Ganga Pharma, Senbo Industries, Decipher Labs, Secunderabad Health., Hind Bio Sciences, Omkar Pharmachem.
Market Cap of Adline Chem Lab is ₹7 Crs.
While the median market cap of its peers are ₹8 Crs.

Adline Chem Lab seems to be less financially stable compared to its competitors.
Altman Z score of Adline Chem Lab is 0 and is ranked 6 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material